AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03722771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inhalation
Description: lavender oil inhalation in a separate room for 3 minutes prior to surgery
Study NCT03722771 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Anxiety Questionnaires 1
Description: Modified Dental Anxiety Scale was used to describe the level of the dental anxiety.
Study NCT03722771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety Questionnaires 1
Description: Modified Dental Anxiety Scale was used to describe the level of the dental anxiety.
Study NCT03722771 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Anxiety Questionnaires 2
Description: State-Trait Anxiety Inventory-State Scale was used to distinguish the true anxiety level of the patients from the anxiety level for a particular situation.
Study NCT03722771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety Questionnaires 2
Description: State-Trait Anxiety Inventory-State Scale was used to distinguish the true anxiety level of the patients from the anxiety level for a particular situation.
Study NCT03722771 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Vital Signs 1
Description: Changes in vital signs 1 - blood pressure - before, during and after the procedure were noted.
Study NCT03722771 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vital Signs 1
Description: Changes in vital signs 1 - blood pressure - before, during and after the procedure were noted.
Study NCT03722771 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Vital Signs 2
Description: Changes in vital signs 2 - respiratory rate - before, during and after the procedure were noted.
Study NCT03722771 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vital Signs 2
Description: Changes in vital signs 2 - respiratory rate - before, during and after the procedure were noted.
Study NCT03722771 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Vital Signs 3
Description: Changes in vital signs 3 - heart rate - before, during and after the procedure were noted.
Study NCT03722771 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vital Signs 3
Description: Changes in vital signs 3 - heart rate - before, during and after the procedure were noted.
Study NCT03722771 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Vital Signs 4
Description: Changes in vital signs 4 - saturation - before, during and after the procedure were noted.
Study NCT03722771 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vital Signs 4
Description: Changes in vital signs 4 - saturation - before, during and after the procedure were noted.
Study NCT01423149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combretastatin A-4 Phosphate
Description: Combretastatin A-4 Phosphate is administered on Day 0 and Day 7 (+/- 2 days). If the treating ophthalmologist notes any leakage from CNV in the study eye on a fluorescein angiography during the study or an increase in subretinal fluid on an optical coherence tomography measurement, retreatment with Combretastatin A-4 Phosphate is recommended with up to 3 additional treatments. The retreatment visit(s) could occur during a scheduled visit or at an additional visit 1 week after a regular study visit. A post-retreatment follow-up visit is necessary.
Study NCT03563885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bariatric surgery
Description: subjects already scheduled Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) surgery
Study NCT00846898 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: cinnamon 2g per day for 12 weeks
Description: Subjects in intervention group will receive cinnamon capsules for 12 weeks period. The 2 g dose of cinnamon will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
Study NCT00846898 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cinnamon 2g per day for 12 weeks
Description: Subjects in intervention group will receive cinnamon capsules for 12 weeks period. The 2 g dose of cinnamon will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
Study NCT02153723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate
Study NCT01332968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion will be administered on Day 1, 8, and 15 of Cycle 1 and then on Day 1 of each subsequent cycle during induction period and obinutuzumab 1000 mg IV infusion every 2 months during maintenance period.
Study NCT01332968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.
Study NCT01332968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.
Study NCT01332968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.
Study NCT01332968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.
Study NCT01332968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV will be administered on Day 1 of each cycle during induction period.
Study NCT01332968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV will be administered on Day 1 of each cycle during induction period.
Study NCT01332968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 100 mg (or equivalent prednisolone or methylprednisolone) will be administered orally on Days 1-5 of each cycle during induction period.
Study NCT01332968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 100 mg (or equivalent prednisolone or methylprednisolone) will be administered orally on Days 1-5 of each cycle during induction period.
Study NCT01332968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine 90 mg/m\^2 IV infusion will be administered on Days 1 and 2 of each cycle during induction period.
Study NCT01332968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine 90 mg/m\^2 IV infusion will be administered on Days 1 and 2 of each cycle during induction period.
Study NCT01332968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375 milligrams per square meter (mg/m\^2) IV infusion will be administered on Day 1 of each cycle during induction period and rituximab 375 mg/m\^2 every 2 months during maintenance period.
Study NCT02319837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Study NCT02319837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (No longer applicable in Open Label study period)
Description: Sugar pill to mimic enzalutamide
Study NCT02319837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Open Label
Study NCT04265469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetic foot education
Description: Give Diabetic foot education via mobile phone
Study NCT02693392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral hypoglycemic agents (pre-specified) [Metformin, Sulfonylurea]
Description: Patients receiving either of the following oral hypoglycemic agents~1. Sulfonylurea based oral hypoglycemic agents~2. Metformin based oral hypoglycemic agents~3. Metformin plus Sulfonylurea based oral hypoglycemic agents
Study NCT02693392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral hypoglycemic agents (pre-specified) [Metformin, Sulfonylurea]
Description: Patients receiving either of the following oral hypoglycemic agents~1. Sulfonylurea based oral hypoglycemic agents~2. Metformin based oral hypoglycemic agents~3. Metformin plus Sulfonylurea based oral hypoglycemic agents
Study NCT02693392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fenugreek Seed extract
Description: Patients recruited in the study arm will receive Capsule Fenfuro 500 milligram twice daily for 12 weeks as add-on intervention to the pre-specified oral hypoglycemic agents therapy
Study NCT01570868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Starting dose: 45 mg by mouth once daily.
Study NCT03361267 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori PCR test
Description: Clarithromycin resistance (-) Triple therapy (rabeprazole 20 mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid) for 7 days Clarithromycin resistance (+) Bismuth containing quadruple therapy (rabeprazole 20 mg bid, metronidazole 500 mg tid, bismuth 300 mg qid, tetracycline 500mg qid) for 7 days
Study NCT03361267 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CLO test
Description: CLO test : negative --> drop out CLO test : postive --> bismuth containing quadruple therapy
Study NCT00447317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BalanceWise-PD
Description: Dietary counseling based on Social Cognitive Theory, paired with PDA-based dietary self-monitoring
Study NCT00447317 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attention control
Description: Standard peritoneal dialysis dietary education
Study NCT03810391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol
Description: intravenous loading dose of 15ug/kg butorphanol,and followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion until the Ramsay sedation score reached 4 points
Study NCT03810391 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: physiological saline
Description: intravenous infusion of the same volume of physiological saline
Study NCT06304038 — intervention group
Intervention type: DRUG
Intervention: Flu Vaccine
Description: Administration of quadrivalent split inactivated non-adjuvanted flu vaccine Fluarix Tetra
Study NCT00508898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Patients will receive calcitriol (oral capsule) at a fixed dose of 1 mcg twice weekly.
Study NCT00508898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: Patients will receive multivitamin 1 tab daily (with vitamin D2 300 IU).
Study NCT03538821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intact cod protein from fillet
Description: Intact cod protein from fillet 8 g protein daily for 8 weeks
Study NCT03538821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intact cod protein from residual material
Description: Intact cod protein from residual material, 8 g protein daily for 8 weeks
Study NCT03538821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: Control group receive tablet containing fillers
Study NCT04211168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab plus Lenvatinib
Description: Toripalimab 240mg, every 3 weeks, intravenous infused, day 1, 6 weeks a cycle.~Lenvatinib 8mg (weight\<60kg) or 12mg (weight≥60kg), once a day, orally, day 2, 6 weeks a cycle. Dose reduction to 4mg/d or dose termination is allowed according to adverse events.~Number of cycle: until progression or unacceptable toxicity events develop.
Study NCT04151329 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAT1306 and BAT8001 2.4mg/kg
Description: Phase 1 dose titration study of BAT1306 and BAT8001 2.4mg/kg , then choose a proper dose for amplification study based on DLT result
Study NCT04151329 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAT1306 and BAT8001 3.6mg/kg
Description: Phase 1 dose titration study of BAT1306 and BAT8001 3.6mg/kg , then choose a proper dose for amplification study based on DLT result
Study NCT00923936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Doxorubicin
Description: Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m\^2 and bevacizumab every 3 weeks for six cycles.
Study NCT00923936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m\^2 and bevacizumab every 3 weeks for six cycles. Maintenance phase dose: IV bevacizumab every 3 weeks for 11 cycles.
Study NCT03469050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin delayed released 400mg Tablet
Description: Rifaximin delayed released
Study NCT04304287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative autologous blood donation, 14 days before surgery
Study NCT04304287 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative autologous blood donation, 72 hours before surgery
Study NCT04304287 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Without preoperative blood donation
Study NCT03410745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise.
Description: Moderate to heavy intensity resistance exercise consisting of leg press.
Study NCT00780598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tosedostat
Description: In Part A, approximately 70 subjects will be randomized to one of 2 dose regimens of tosedostat which will be administered orally, once daily. The dose regimens of tosedostat will be:~* 120 mg for 6 months once daily, OR~* 240 mg (induction dose) once daily for 2 months, followed by 120 mg(maintenance dose) for 4 months~In Part B a further 130 subjects will receive the dose regimen of tosedostat identified in Part A as being appropriate, based on the interim analysis during Part A.
Study NCT00656695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iminoral
Description: Iminoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
Study NCT00712244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DisCoVisc
Description: Use of DisCoVisc Ophthalmic Viscosurgical Device (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery.
Study NCT00712244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DuoVisc
Description: Use of DuoVisc viscoelastic system consisting of Viscoat (3% sodium hyaluronate, 4% chondroitin sulfate)and Provisc(1% sodium hyaluronate) during cataract surgery.
Study NCT00712244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Healon5
Description: Use of Healon5 ophthalmic viscosurgical device (2.3% Sodium Hyaluronate) during cataract surgery.
Study NCT03469050 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID + Placebo BID
Study NCT03469050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo BID + Placebo BID
Study NCT00969813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Single 10 mg dose of CP-690,550
Study NCT00586066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Week 0: 5 mg memantine or placebo once a day (q.d.) Week 1: 5 mg memantine or placebo twice a day (b.i.d.) Week 2-3: 5 mg memantine or placebo once in the morning (q.a.m.)/10 mg once in the evening (q.p.m.) Week 4-12: 10mg Memantine or placebo b.i.d.
Study NCT00712244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amvisc Plus
Description: Use of Amvisc Plus ophthalmic viscosurgical device (1.6% Sodium Hyaluronate) during cataract surgery.
Study NCT01358253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2)(odd courses).
Study NCT00656695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoral
Description: Neoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
Study NCT02788292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Description: See arm description
Study NCT03607110 — intervention group
Intervention type: DRUG
Intervention: Ketamine
Description: sedation drugs
Study NCT03607110 — intervention group
Intervention type: DRUG
Intervention: fentanyl
Description: sedation drugs
Study NCT03607110 — intervention group
Intervention type: DEVICE
Intervention: patient control analgesia
Description: patient control analgesia
Study NCT00661687 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Currently Marketed PureVision Contact Lens.
Description: Contact lens for continuous wear
Study NCT00661687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alternate Design of the PureVision Contact Lens.
Description: Contact lens for continuous wear
Study NCT05308719 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: High Flow Nasal Therapy
Description: High Flow Nasal Oxygen (Airvo2 Device)
Study NCT00912509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: riboflavin
Description: riboflavin 0.1% is applied every 2 minutes for 30 minutes
Study NCT00912509 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UVX Light
Description: UVX 365 nm wavelength light source is applied with continued application of riboflavin 0.1%
Study NCT01234376 — intervention group
Intervention type: DEVICE
Intervention: Confocal laser endomicroscopy
Description: Confocal laser endomicroscopy
Study NCT00586066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive comparator. Placebo-matching memantine tablet.
Study NCT01131767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium & Pseudoephedrine HCl
Description: Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
Study NCT01131767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium & Pseudoephedrine HCl
Description: Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
Study NCT02837952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FDC IBU/APAP 250 mg/500 mg
Description: FDC IBU/APAP 250 mg/500 mg
Study NCT02837952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02908243 — intervention group
Intervention type: OTHER
Intervention: collection of baseline data
Description: collection of baseline data including ages, types, severity, inhibitors and comorbidities
Study NCT00935207 — intervention group
Intervention type: OTHER
Intervention: Pediatric Pain Diary
Description: Pain diary designed for pediatric patients
Study NCT00003907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
Study NCT00003907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
Study NCT00003907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitomycin
Description: Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
Study NCT00003907 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: embolization
Description: Immediately following delivery of the chemoemulsion, particulate embolization is performed. The particulate embolic material is prepared on a separate table or tray, using absorbable gelatin sponge (Gelfoam, Upjohn, Kalamazoo, MI), in either powder or pledget form. Approximately 1 g of this temporary occlusive agent is dissolved in 20-30 cc of full-strength contrast with 2.4 cc of absolute alcohol.
Study NCT02450188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vardenafil
Description: In this study we used Vardenafil 10 mg orodispersible tablets. These are the only orodispersible tablets on commerce indicated for the treatment of ED. We choose this kind of tablets because of their easy way of assumption that can also have a minor psychological impact on patients.~Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks.
Study NCT01177306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended release guanfacine
Description: 1-4 mg daily. Dose determined by response of ADHD symptoms to drug and by body mass limitations